2022 World Conference on Lung Cancer (ePosters)-EP04.01-022. Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression

EP04.01-022. Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression

Back to course

Pdf Summary

This study aimed to assess the real-world evidence (RWE) of durvalumab, an immunotherapy drug, for stage III non-small cell lung cancer (NSCLC). The study analyzed data from patients in Brazil who received durvalumab between August 2017 and February 2022. The primary endpoint was the median overall survival (OS), and the secondary endpoints included time to treatment discontinuation (TTD), post-progression regimen, and time to treatment discontinuation of subsequent therapy (TTD2).<br /><br />The study included 177 patients with a median follow-up of 12 months. The median TTD for durvalumab was 7.9 months. Among the patients who discontinued durvalumab, 27% received a subsequent treatment regimen compared to 18% of patients who completed 12 months of durvalumab. The choice of subsequent regimen also varied depending on whether patients completed the treatment with durvalumab or not. The median OS was 34.9 months, with a 12-month survival rate of 85% and a 24-month survival rate of 71%. Immune checkpoint inhibitors, either as monotherapy or combined with chemotherapy, were the preferred regimen for 11 patients and achieved a median TTD2 of 6.2 months.<br /><br />The results of this study confirm the effectiveness of durvalumab in stage III NSCLC, with a median OS and survival rates comparable to previous clinical trials. However, data on subsequent therapy was limited due to a short follow-up period, but it was found to differ based on the duration of durvalumab treatment.<br /><br />Overall, this RWE study provides valuable insights into the use and outcomes of durvalumab in stage III NSCLC patients, highlighting the importance of considering real-world evidence alongside clinical trials to inform clinical decision-making and patient care.

Asset Subtitle

Pedro Aguiar Jr

Meta Tag

Speaker Pedro Aguiar Jr

Topic Global Health, Health Services Research, and Health Economics - Cost Issues

Keywords

real-world evidence

durvalumab

immunotherapy drug

stage III non-small cell lung cancer

NSCLC

overall survival

time to treatment discontinuation

post-progression regimen

subsequent therapy

immune checkpoint inhibitors